Sector News

Sanofi cancer executive jumps ship to Silicon Therapeutics

October 17, 2017
Life sciences

Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon, becoming the latest in an increasingly long line of Big Pharma executives to join the early-stage life science stream.

Winter comes to the Boston-based company from Sanofi, where since 2013 he led its U.S. oncology research as site lead and research cluster head on overcoming immunosuppression.

This comes as Sanofi has once again been retooling its cancer R&D, bringing a deeper focus into key oncology areas after seemingly looking to scale down just a few years back.

Winter, also a Blueprint Medicines, Merck Research Laboratories and Exelixis alumnus, will work with Silicon and its “integrated physics-based drug discovery,” where it is looking to create small molecule therapeutics for diseases with challenging protein targets that are difficult to drug.

“Silicon Therapeutics has assembled a world-class team applying an industry-leading platform to address fundamental challenges for designing next-generation, breakthrough therapeutics,” said Winter.

“I’m excited to join Silicon Therapeutics’ mission that joins integrated excellence in physics-based simulations, chemistry and disease biology focused on making drugs that matter for patients.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).